Does COVID-19 Infection Increase the Risk of Diabetes? Current Evidence.

IF 5.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Current Diabetes Reports Pub Date : 2023-08-01 Epub Date: 2023-06-07 DOI:10.1007/s11892-023-01515-1

Rachel Wong, Emily Lam, Carolyn T Bramante, Steven G Johnson, Jane Reusch, Kenneth J Wilkins, Hsin-Chieh Yeh

{"title":"Does COVID-19 Infection Increase the Risk of Diabetes? Current Evidence.","authors":"Rachel Wong, Emily Lam, Carolyn T Bramante, Steven G Johnson, Jane Reusch, Kenneth J Wilkins, Hsin-Chieh Yeh","doi":"10.1007/s11892-023-01515-1","DOIUrl":null,"url":null,"abstract":"Purpose of review: Multiple studies report an increased incidence of diabetes following SARS-CoV-2 infection. Given the potential increased global burden of diabetes, understanding the effect of SARS-CoV-2 in the epidemiology of diabetes is important. Our aim was to review the evidence pertaining to the risk of incident diabetes after COVID-19 infection.Recent findings: Incident diabetes risk increased by approximately 60% compared to patients without SARS-CoV-2 infection. Risk also increased compared to non-COVID-19 respiratory infections, suggesting SARS-CoV-2-mediated mechanisms rather than general morbidity after respiratory illness. Evidence is mixed regarding the association between SARS-CoV-2 infection and T1D. SARS-CoV-2 infection is associated with an elevated risk of T2D, but it is unclear whether the incident diabetes is persistent over time or differs in severity over time. SARS-CoV-2 infection is associated with an increased risk of incident diabetes. Future studies should evaluate vaccination, viral variant, and patient- and treatment-related factors that influence risk.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"23 8","pages":"207-216"},"PeriodicalIF":5.2000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244847/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-023-01515-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Multiple studies report an increased incidence of diabetes following SARS-CoV-2 infection. Given the potential increased global burden of diabetes, understanding the effect of SARS-CoV-2 in the epidemiology of diabetes is important. Our aim was to review the evidence pertaining to the risk of incident diabetes after COVID-19 infection.

Recent findings: Incident diabetes risk increased by approximately 60% compared to patients without SARS-CoV-2 infection. Risk also increased compared to non-COVID-19 respiratory infections, suggesting SARS-CoV-2-mediated mechanisms rather than general morbidity after respiratory illness. Evidence is mixed regarding the association between SARS-CoV-2 infection and T1D. SARS-CoV-2 infection is associated with an elevated risk of T2D, but it is unclear whether the incident diabetes is persistent over time or differs in severity over time. SARS-CoV-2 infection is associated with an increased risk of incident diabetes. Future studies should evaluate vaccination, viral variant, and patient- and treatment-related factors that influence risk.

Abstract Image

查看原文本刊更多论文

COVID-19 感染会增加糖尿病风险吗？当前证据。

审查目的：多项研究报告称，感染 SARS-CoV-2 后糖尿病发病率增加。鉴于糖尿病可能会增加全球负担，了解 SARS-CoV-2 对糖尿病流行病学的影响非常重要。我们的目的是回顾有关感染 COVID-19 后糖尿病发病风险的证据：与未感染 SARS-CoV-2 的患者相比，发生糖尿病的风险增加了约 60%。与未感染 COVID-19 的呼吸道感染相比，发病风险也增加了，这表明 SARS-CoV-2 介导的机制而非呼吸道疾病后的一般发病率。关于 SARS-CoV-2 感染与 T1D 的关系，目前证据不一。SARS-CoV-2 感染与 T2D 风险升高有关，但目前还不清楚糖尿病是否会随着时间的推移而持续，或随着时间的推移其严重程度有所不同。SARS-CoV-2 感染与糖尿病发病风险升高有关。未来的研究应评估疫苗接种、病毒变异以及影响风险的患者和治疗相关因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.